Literature DB >> 31197020

Modeling Corticosteroid Pharmacokinetics and Pharmacodynamics, Part I: Determination and Prediction of Dexamethasone and Methylprednisolone Tissue Binding in the Rat.

Vivaswath S Ayyar1, Dawei Song1, Debra C DuBois1, Richard R Almon1, William J Jusko2.   

Abstract

The plasma and tissue binding properties of two corticosteroids, dexamethasone (DEX) and methylprednisolone (MPL), were assessed in the rat in anticipation of developing physiologically based pharmacokinetic and pharmacokinetic/pharmacodynamic models. The tissue-to-plasma partition coefficients (K P) of DEX and MPL were measured in liver, muscle, and lung in vivo after steady-state infusion and bolus injection in rats. Since K P is often governed by reversible binding to macromolecules in blood and tissue, an attempt was made to assess K P values of DEX and MPL by in vitro binding studies using rat tissue homogenates and to compare these estimates to those obtained from in vivo kinetics after dosing. The K P values of both steroids were also calculated in rat tissues using mechanistic tissue composition-based equations. The plasma binding of DEX and MPL was linear with moderate binding (60.5% and 82.5%) in male and female rats. In vivo estimates of steroid uptake appeared linear across the tested concentrations and K P was highest in liver and lowest in muscle for both steroids. Assessment of hepatic binding of MPL in vitro was severely affected by drug loss at 37°C in male liver homogenates, whereas DEX was stable in both male and female liver homogenates. With the exception of MPL in liver, in vitro-derived K P estimates reasonably agreed with in vivo values. The mechanistic equations modestly underpredicted K P for both drugs. Tissue metabolism, saturable tissue binding, and active uptake are possible factors that can complicate assessments of in vivo tissue binding of steroids when using tissue homogenates. SIGNIFICANCE STATEMENT: Assuming the free hormone hypothesis, the ratio of the unbound drug fraction in plasma and in tissues defines the tissue-to-plasma partition coefficient (K P), an important parameter in physiologically based pharmacokinetic modeling that determines total drug concentrations within tissues and the steady-state volume of distribution. This study assessed the plasma and tissue binding properties of the synthetic corticosteroids, dexamethasone and methylprednisolone, in rats using ultrafiltration and tissue homogenate techniques. In vitro-in vivo and in silico-in vivo extrapolation of K P was assessed for both drugs in liver, muscle, and lung. Although the extrapolation was fairly successful across the tissues, in vitro homogenate studies severely underpredicted the K P of methylprednisolone in liver, partly attributable to the extensive hepatic metabolism.
Copyright © 2019 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31197020      PMCID: PMC6658919          DOI: 10.1124/jpet.119.257519

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  46 in total

Review 1.  Methods of determining plasma and tissue binding of drugs. Pharmacokinetic consequences.

Authors:  G M Pacifici; A Viani
Journal:  Clin Pharmacokinet       Date:  1992-12       Impact factor: 6.447

2.  Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases.

Authors:  Trudy Rodgers; David Leahy; Malcolm Rowland
Journal:  J Pharm Sci       Date:  2005-06       Impact factor: 3.534

Review 3.  Protein binding of antimicrobials: clinical pharmacokinetic and therapeutic implications.

Authors:  W A Craig; P G Welling
Journal:  Clin Pharmacokinet       Date:  1977 Jul-Aug       Impact factor: 6.447

Review 4.  Factors affecting drug metabolism.

Authors:  J R Gillette
Journal:  Ann N Y Acad Sci       Date:  1971-07-06       Impact factor: 5.691

Review 5.  Binding of drugs to tissues.

Authors:  H Kurz; B Fichtl
Journal:  Drug Metab Rev       Date:  1983       Impact factor: 4.518

6.  Relationship between Plasma Albumin Concentration and Plasma Volume in 5 Inbred Rat Strains.

Authors:  Rajiv Rose; Harold G Klemcke
Journal:  J Am Assoc Lab Anim Sci       Date:  2015-09       Impact factor: 1.232

7.  Modeling Combined Immunosuppressive and Anti-inflammatory Effects of Dexamethasone and Naproxen in Rats Predicts the Steroid-Sparing Potential of Naproxen.

Authors:  Xiaonan Li; Debra C DuBois; Dawei Song; Richard R Almon; William J Jusko; Xijing Chen
Journal:  Drug Metab Dispos       Date:  2017-04-17       Impact factor: 3.922

8.  Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratios.

Authors:  J Cory Kalvass; Tristan S Maurer; Gary M Pollack
Journal:  Drug Metab Dispos       Date:  2007-01-19       Impact factor: 3.922

9.  6 alpha-Methylprednisolone and 6 alpha-methylprednisone plasma protein binding in humans and rabbits.

Authors:  W F Ebling; R L Milsap; S J Szefler; W J Jusko
Journal:  J Pharm Sci       Date:  1986-08       Impact factor: 3.534

10.  Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.

Authors:  A H Schinkel; E Wagenaar; L van Deemter; C A Mol; P Borst
Journal:  J Clin Invest       Date:  1995-10       Impact factor: 14.808

View more
  9 in total

1.  Physiologically Based Pharmacokinetics of Dexamethasone in Rats.

Authors:  Dawei Song; Le Sun; Debra C DuBois; Richard R Almon; Shengnan Meng; William J Jusko
Journal:  Drug Metab Dispos       Date:  2020-06-29       Impact factor: 3.922

2.  Seeking Nonspecific Binding: Assessing the Reliability of Tissue Dilutions for Calculating Fraction Unbound.

Authors:  William J Jusko; Emilie A G Molins; Vivaswath S Ayyar
Journal:  Drug Metab Dispos       Date:  2020-08-05       Impact factor: 3.922

3.  Physiologically Based Pharmacokinetic Modeling Involving Nonlinear Plasma and Tissue Binding: Application to Prednisolone and Prednisone in Rats.

Authors:  Xiaonan Li; Debra C DuBois; Richard R Almon; William J Jusko
Journal:  J Pharmacol Exp Ther       Date:  2020-09-03       Impact factor: 4.030

4.  Modeling Corticosteroid Pharmacokinetics and Pharmacodynamics, Part II: Sex Differences in Methylprednisolone Pharmacokinetics and Corticosterone Suppression.

Authors:  Vivaswath S Ayyar; Debra C DuBois; Toshimichi Nakamura; Richard R Almon; William J Jusko
Journal:  J Pharmacol Exp Ther       Date:  2019-06-13       Impact factor: 4.030

Review 5.  Transitioning from Basic toward Systems Pharmacodynamic Models: Lessons from Corticosteroids.

Authors:  Vivaswath S Ayyar; William J Jusko
Journal:  Pharmacol Rev       Date:  2020-04       Impact factor: 25.468

6.  Modeling Corticosteroid Pharmacokinetics and Pharmacodynamics, Part III: Estrous Cycle and Estrogen Receptor-Dependent Antagonism of Glucocorticoid-Induced Leucine Zipper (GILZ) Enhancement by Corticosteroids.

Authors:  Vivaswath S Ayyar; Debra C DuBois; Richard R Almon; William J Jusko
Journal:  J Pharmacol Exp Ther       Date:  2019-06-13       Impact factor: 4.030

7.  A Pharmacokinetic and Metabolism Study of the TRPC6 Inhibitor SH045 in Mice by LC-MS/MS.

Authors:  Xiao-Ning Chai; Friedrich-Alexander Ludwig; Anne Müglitz; Yuanyuan Gong; Michael Schaefer; Ralf Regenthal; Ute Krügel
Journal:  Int J Mol Sci       Date:  2022-03-26       Impact factor: 5.923

8.  Is PTSD-Phenotype Associated with HPA-Axis Sensitivity? Feedback Inhibition and Other Modulating Factors of Glucocorticoid Signaling Dynamics.

Authors:  Dor Danan; Doron Todder; Joseph Zohar; Hagit Cohen
Journal:  Int J Mol Sci       Date:  2021-06-03       Impact factor: 5.923

9.  High-dose methylprednisolone in nonintubated patients with severe COVID-19 pneumonia.

Authors:  Aikaterini Papamanoli; Jeanwoo Yoo; Prabhjot Grewal; William Predun; Jessica Hotelling; Robin Jacob; Azad Mojahedi; Hal A Skopicki; Mohamed Mansour; Luis A Marcos; Andreas P Kalogeropoulos
Journal:  Eur J Clin Invest       Date:  2020-12-01       Impact factor: 5.722

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.